Chemicals

Methyl trifluoromethanesulfonate Cas:333-27-7

We are Methyl trifluoromethanesulfonate CAS:333-27-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Synonyms：

methyl-triflate

Methanesulfonic acid,trifluoro-,methyl ester

Methyl triflate

Methyl trifluoromethanesulphonate

Trifluoromethanesulfonic Acid Methyl Ester

Methyltrifluoromethanesulfonate

trifluoromethanesulphonic acid methyl ester

Methyl Trifluoromethanesulfonate

EINECS 206-371-7

Methyl trifluoromethane sulfonate

Molecular Formula: C2H3F3O3S

Molecular weight： 164.10400

Appearance and properties: colorless liquid

Density: 1.45 g/mL at 25 °C(lit.)

Boiling point: 94-99 °C(lit.)

Flash point: 101 °F

Refractive index: n20/D 1.326(lit.)

Stability: Stable under normal temperatures and pressures. Storage conditions: 0-6ºC

Our company is committed to establishing a complete fluorochemical products and technology platform to provide customers with convenient one-stop services. Our products are widely used in the manufacture of new materials, pharmaceutical research and development and the development of new pesticides. The fluorine product categories include fluorine-containing material raw materials, fluorinated reagents, fluorine-containing building blocks, fluorine-containing reagents and fluorine-containing gases for synthesis. Shanghai Fluorine Technology will strive to build a complete industrial chain from fluorine-containing raw material procurement, fluorination technology research and development, fluorine-containing product production, fluorine-containing product storage, fluorine-containing product quality control and fluorine-containing product application.

Market News: Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly.Fructose-1-phosphate manufacturer.In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion. 3-(2-oxo-cyclopentylidenemethyl)-1H-indole-5-carbonitrile supplier Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. 3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-thioxanthen-9-one producer

Product Name
2-(2-methyl-1H-indol-3-yl)ethanamine	View Details
α,α-trehalose	View Details
Methyl hexadecanoate	View Details